Modulated anti-VEGF therapy under the influence of lipid metabolizing proteins in Age related macular degeneration: a pilot study

• Published in: Scientific reports Vol. 12; no. 1; p. 714
• Main Authors: Sharma, Kaushal, Battu, Priya, Singh, Ramandeep, Sharma, Suresh Kumar, Anand, Akshay
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13.01.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/208/1516; 631/208/176; 631/208/200; 631/208/2490; Acuity; Age; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - pharmacology; Apolipoprotein E; Apolipoproteins E - genetics; Apolipoproteins E - metabolism; Bevacizumab - administration & dosage; Bevacizumab - pharmacology; Female; Gene Expression; Genotypes; Humanities and Social Sciences; Humans; Intravitreal Injections; Lipase - genetics; Lipase - metabolism; Lipid Metabolism - genetics; Lipids; Macular degeneration; Macular Degeneration - drug therapy; Macular Degeneration - genetics; Macular Degeneration - metabolism; Male; multidisciplinary; Patients; Pilot Projects; Population genetics; Science; Science (multidisciplinary); Treatment Outcome; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-04269-6

Age-related macular degeneration (AMD) is a devastating retinal disease that results in irreversible vision loss in the aged population. The complex genetic nature and degree of genetic penetrance require a redefinition of the current therapeutic strategy for AMD. We aimed to investigate the role of modifiers for current anti-VEGF therapy especially for non-responder AMD patients. We recruited 78 wet AMD cases (out of 278 AMD patients) with their socio-demographic and treatment regimen. Serum protein levels were estimated by ELISA in AMD patients. Data pertaining to the number of anti-VEGF injections given (in 1 year) along with clinical images (FFA and OCT) of AMD patients were also included. Visual acuity data (logMAR) for 46 wet AMD cases out of a total of 78 patients were also retrieved to examine the response of anti-VEGF injections in wet AMD cases. Lipid metabolizing genes (LIPC and APOE) have been identified as chief biomarkers for anti-VEGF response in AMD patients. Both genotypes ‘CC’ and ‘GC’ of LIPC have found to be associated with a number of anti-VEGF injections in AMD patients which could influence the expression of B3GALTL,HTRA1, IER3, LIPC and SLC16A8 proteins in patients bearing both genotypes as compared to reference genotype. Elevated levels of APOE were also observed in group 2 wet AMD patients as compared to group 1 suggesting the significance of APOE levels in anti-VEGF response. The genotype of B3GALTL has also been shown to have a significant association with the number of anti-VEGF injections. Moreover, visual acuity of group 1 (≤ 4 anti-VEGF injections/year) AMD patients was found significantly improved after 3 doses of anti-VEGF injections and maintained longitudinally as compared to groups 2 and 3. Lipid metabolising genes may impact the outcome of anti-VEGF AMD treatment.